Compare Johnson & Johnson (JNJ) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Johnson & Johnson trades at $250.05 (market cap $598.96B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.64. The key difference: Johnson & Johnson pays a 2.15% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | VTIP | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $50.75 |
52-Week Low | $164.36 | $49.39 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VTIP trades at $49.665, down 0.07% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The ETF focuses on short-term inflation-protected securities, offering a hedge against rising costs. Recent institutional buying includes a 239.8% position increase by Cwm LLC as of April 2026, signaling confidence. A dividend of $0.68 is scheduled for July 2026, providing income appeal.
Outlook remains cautious as the Fed signals no rate cuts in 2026, potentially limiting bond upside. VTIP's inflation hedge is relevant with CPI at 3.8% in April 2026, but short-term rate sensitivity poses risks. The ETF suits defensive portfolios seeking inflation protection, though volatility may persist amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
